Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

204 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).
Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. Cardoso F, et al. Among authors: biganzoli l. Ann Oncol. 2017 Jan 1;28(1):16-33. doi: 10.1093/annonc/mdw544. Ann Oncol. 2017. PMID: 28177437 Free PMC article. No abstract available.
Adjuvant systemic therapy for breast cancer.
Piccart MJ, Biganzoli L, Roy JA. Piccart MJ, et al. Among authors: biganzoli l. Curr Opin Oncol. 1996 Nov;8(6):478-84. doi: 10.1097/00001622-199611000-00006. Curr Opin Oncol. 1996. PMID: 8971467 Review.
An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes.
Awada A, Biganzoli L, Cufer T, Beex L, Lohrisch C, Batter V, Hamilton A, Nooij M, Piccart M. Awada A, et al. Among authors: biganzoli l. Eur J Cancer. 2002 Apr;38(6):773-8. doi: 10.1016/s0959-8049(01)00427-0. Eur J Cancer. 2002. PMID: 11937310 Clinical Trial.
Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial.
Biganzoli L, Cufer T, Bruning P, Coleman R, Duchateau L, Calvert AH, Gamucci T, Twelves C, Fargeot P, Epelbaum R, Lohrisch C, Piccart MJ. Biganzoli L, et al. J Clin Oncol. 2002 Jul 15;20(14):3114-21. doi: 10.1200/JCO.2002.11.005. J Clin Oncol. 2002. PMID: 12118025 Clinical Trial.
EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer.
Hamilton A, Biganzoli L, Coleman R, Mauriac L, Hennebert P, Awada A, Nooij M, Beex L, Piccart M, Van Hoorebeeck I, Bruning P, de Valeriola D. Hamilton A, et al. Among authors: biganzoli l. Ann Oncol. 2002 Jun;13(6):910-8. doi: 10.1093/annonc/mdf157. Ann Oncol. 2002. PMID: 12123337 Free article. Clinical Trial.
An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer.
Bonnefoi H, Biganzoli L, Mauriac L, Cufer T, Schaefer P, Atalay G, Piccart M. Bonnefoi H, et al. Among authors: biganzoli l. Eur J Cancer. 2003 Jun;39(9):1277-83. doi: 10.1016/s0959-8049(03)00266-1. Eur J Cancer. 2003. PMID: 12763217 Clinical Trial.
204 results